Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
darunavir (Prezista®)
Reference No. 2579
Publication date:
16/07/2015
Appraisal information
darunavir (Prezista®) 75 mg film-coated tablet
darunavir (Prezista®) 150 mg film-coated tablet
darunavir (Prezista®) 300 mg film-coated tablet
darunavir (Prezista®) 600 mg film-coated tablet
darunavir (Prezista®) 800 mg film-coated tablet
darunavir (Prezista®) 100 mg/ml oral suspension
Company:
Janssen-Cilag Ltd
BNF category:
Infections
NMG meeting date:
13/05/2015
AWMSG meeting date:
17/06/2015
Submission Type:
Limited Submission
Status:
Recommended
Advice No:
1815
Ratification by Welsh Government:
15/07/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Darunavir (Prezista®) co-administered with low dose ritonavir in combination with other antiretroviral medicinal products is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients from the age of three years and at least 15 kg body weight.
Final Appraisal Recommendation (FAR)
Download
darunavir (Prezista) 2579 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
daruavir (Prezista) 2579 ASAR
darunavir (Prezista) 2246 ASAR
darunavir (Prezista) 403 ASAR
Clinical Expert (CE) Summary
Download
darunavir (Prezista) 2579 CE summary